| Phase I study of atacicept in relapsed/refractory multiple myeloma (MM) and Waldenström's macroglobulinemia. | |
| | |
MedLine Citation:
|
PMID: 21454215 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Atacicept, a specific inhibitor of BLys and APRIL, was used in a phase I study for 14 patients with myeloma (MM) and 4 with Waldenström's macroglobulinemia (WM). They received 1 cycle of 5 once-weekly s.c. injections, followed by an extension if in stable disease or in response. The maximum tolerated dose was not identified. Of 11 patients with MM who completed initial treatment, 5 patients were progression-free after cycle 1 and 4 patients were progression-free after extended therapy. Of 4 patients with WM, 3 patients were progression-free after cycle 1. Polyclonal immunoglobulin isotypes and total B cells were reduced. Plasma concentrations of soluble CD 138 decreased. Biological effect was more pronounced in WM. Of the 16 patients tested at baseline, 13 had measurable levels of free APRIL (≥25 ng/mL). In this small series, no correlations were apparent between baseline levels of free APRIL and biological or clinical response criteria. |
| | |
Authors:
|
Jean-François Rossi |
Related Documents
:
|
21314275 - Il-6 polymorphism associated with fatal outcome in patients with severe traumatic brain... 21145805 - An apoptosis panel for nonalcoholic steatohepatitis diagnosis. 21276075 - A patient selection score for cardiac resynchronization therapy. 12185025 - Using a dopamine type 1a receptor agonist in high-risk patients to ameliorate contrast-... 1621485 - Evidence of intrathyroidal accumulation of tsh receptor antibody in graves' disease. 9045215 - Effect of varying atrial sensitivity, av interval, and detection algorithm on automatic... |
Publication Detail:
|
Type: Clinical Trial, Phase I; Journal Article |
Journal Detail:
|
Title: Clinical lymphoma, myeloma & leukemia Volume: 11 ISSN: 2152-2669 ISO Abbreviation: Clin Lymphoma Myeloma Leuk Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-04-01 Completed Date: 2011-08-30 Revised Date: 2011-10-03 |
Medline Journal Info:
|
Nlm Unique ID: 101525386 Medline TA: Clin Lymphoma Myeloma Leuk Country: United States |
Other Details:
|
Languages: eng Pagination: 136-8 Citation Subset: IM |
Affiliation:
|
Department of Haematology, University Hospital, CHU Saint Eloi, Montpellier, France. jf-rossi@chu-montpellier.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Female Humans Male Middle Aged Multiple Myeloma / drug therapy* Recombinant Fusion Proteins / administration & dosage*, adverse effects* Recurrence Waldenstrom Macroglobulinemia / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Recombinant Fusion Proteins; 0/TACI receptor-IgG Fc fragment fusion protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.
Next Document: Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia.